false 0001756262 0001756262 2024-05-23 2024-05-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 23, 2024

 

 

TransMedics Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Massachusetts   001-38891   83-2181531

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

200 Minuteman Road

Andover, Massachusetts

   01810
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (978) 552-0900

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, no par value per share   TMDX   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 23, 2024, TransMedics Group, Inc. (the “Company”) held its 2024 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following proposals:

Proposal One: The shareholders elected Waleed Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania Jr., Stephanie Lovell, Merilee Raines, and David Weill, M.D. as directors, each to serve on the Board of Directors of the Company until the 2025 Annual Meeting of Shareholders or until his or her successor is duly elected and qualified in accordance with our Restated Articles of Organization and Amended and Restated Bylaws, or his or her earlier death, resignation or removal, based on the following votes:

 

Director Nominee    For    Against    Abstain    Broker
Non-Votes

Waleed Hassanein, M.D

        24,024,298        208,947        7,690        2,988,846

James R. Tobin

        23,518,088        711,239        11,608        2,988,846

Edward M. Basile

        19,849,603        4,379,664        11,668        2,988,846

Thomas J. Gunderson

        23,873,171        356,023        11,741        2,988,846

Edwin M. Kania, Jr.

        23,550,271        679,023        11,641        2,988,846

Stephanie Lovell

        23,789,019        441,905        10,011        2,988,846

Merilee Raines

        23,928,824        302,040        10,071        2,988,846

David Weill, M.D.

        23,735,272        494,175        11,488        2,988,846

Proposal Two: The shareholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, based on the following votes:

 

For   Against   Abstain   Broker Non-Votes
22,902,359   1,321,627   16,949   2,988,846

Proposal Three: The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2024, based on the following votes:

 

For   Against   Abstain
26,468,778   748,890   12,113

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      TRANSMEDICS GROUP, INC.
Date: May 28, 2024     By:  

/s/ Stephen Gordon

    Name:   Stephen Gordon
    Title:   Chief Financial Officer and Treasurer
v3.24.1.1.u2
Document and Entity Information
May 23, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001756262
Document Type 8-K
Document Period End Date May 23, 2024
Entity Registrant Name TransMedics Group, Inc.
Entity Incorporation State Country Code MA
Entity File Number 001-38891
Entity Tax Identification Number 83-2181531
Entity Address, Address Line One 200 Minuteman Road
Entity Address, City or Town Andover
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01810
City Area Code (978)
Local Phone Number 552-0900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, no par value per share
Trading Symbol TMDX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
TransMedics (NASDAQ:TMDX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more TransMedics Charts.
TransMedics (NASDAQ:TMDX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more TransMedics Charts.